Loading candles…
Aarey Drugs & Pharmaceuticals Ltd, incorporated in 1990, operates in the pharmaceuticals and chemicals industries in India. The company is engaged in the manufacturing and trading of Active Pharmaceutical Ingredients (APIs), intermediates, various chemicals and solvents, and bulk drugs. It primarily serves the pharmaceutical sector by supplying essential chemical building blocks and bulk drugs. There are no publicly disclosed details about its founders, key management, subsidiaries, or listing on stock exchanges.
This page is a live market overview for AAREY DRUGS & PHARM LTD (AAREYDRUGS) on the NSE. As a listed security, AAREY DRUGS & PHARM LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for AAREYDRUGS before placing trades on tick2trade.
As of the latest feed, AAREYDRUGS last traded at ₹100.49 on NSE, up ₹1.67 (1.69%) from the previous close of ₹98.82. Today's session range is ₹94.15 – ₹101, against a 52-week band of ₹50.31 – ₹101.29. Traded volume today stands at 1.70L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for AAREYDRUGS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether AAREYDRUGS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for AAREY DRUGS & PHARM LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in AAREYDRUGS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated AAREYDRUGS option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 14 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 29 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 11 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
| Unaudited Results - FY25 | To consider and approve the Unaudited financial results for the period ended Jun 30, 2025 | 13 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 30 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.